{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:49:06Z","timestamp":1788544146676,"version":"build-2803163510"},"reference-count":24,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The combination of sofosbuvir\/velpatasvir\/voxilaprevir (SOF\/VEL\/VOX) is recommended as a salvage therapy for treatment-experienced chronic hepatitis C (CHC) patients. However, it is used in our country for treatment-na\u00efve and treatment-experienced patients. This study aims to present real-world data from T\u00fcrkiye on CHC patients treated with SOF\/VEL\/VOX. The present study was conducted by the Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases (KL\u0130M\u0130K). It was a multicenter, retrospective, observational study. The data were collected from patients receiving SOF\/VEL\/VOX therapy at 12 medical centers in T\u00fcrkiye between 1 June 2022 and 31 December 2024. The patients had received the treatment for 8 to 12 weeks. Of the 139 patients enrolled, 63.3% (n = 88) were male, with a mean age of 54.4 years. Most patients were non-cirrhotic (94.2%, n = 131) and treatment-na\u00efve (92%, n = 128); 49.6% (n = 69) were infected with genotype 1b. Early virologic response (EVR) could be assessed in 126 patients, with an EVR rate of 82.5% (n = 104). End-of-treatment data were available for 113 patients, all achieving an end-of-treatment response. Among the 80 patients for whom week-12 post-treatment data were available, 97.5% sustained virologic response at week 12 (SVR12). Significant improvements were observed in AST, ALT, and platelet levels, along with reductions in APRI and FIB-4 scores (p = 0.001).\u201d No serious adverse events leading to treatment discontinuation were reported. Mild adverse events included pruritus (2.1%, n = 3), fatigue (2.1%, n = 3), and nausea (1.4%, n = 2). The SOF\/VEL\/VOX combination is a highly effective and well-tolerated treatment option in treatment-na\u00efve CHC patients, achieving an SVR12 rate of 97.5%.<\/jats:p>","DOI":"10.3390\/v17070931","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T07:55:43Z","timestamp":1751442943000},"page":"931","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir\/Velpatasvir\/Voxilaprevir: A Multicenter Real-World Experience from T\u00fcrkiye"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-9109","authenticated-orcid":false,"given":"Umut Devrim","family":"Binay","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Y\u0131ld\u0131r\u0131m University, 24100 Erzincan, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7368-7187","authenticated-orcid":false,"given":"Faruk","family":"Karake\u00e7ili","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Y\u0131ld\u0131r\u0131m University, 24100 Erzincan, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilgehan","family":"Aygen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erciyes University, 38030 Kayseri, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fin","family":"K\u0131l\u0131n\u00e7 Toker","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Kayseri City Hospital, University of Health Sciences, 38080 Kayseri, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2604-3776","authenticated-orcid":false,"given":"\u0130lhami","family":"\u00c7elik","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Kayseri City Hospital, University of Health Sciences, 38080 Kayseri, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ne\u015fe","family":"Demirt\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03030 Afyonkarahisar, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011f\u00e7e","family":"\u015eim\u015fek Bozok","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Mersin University, 33343 Mersin, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Dursun","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erciyes University, 38030 Kayseri, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fethiye","family":"Akg\u00fcl","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Batman Training and Research Hospital, 72070 Batman, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7635-8848","authenticated-orcid":false,"given":"G\u00fcle","family":"\u00c7\u0131nar","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ankara University, 06230 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7744-4123","authenticated-orcid":false,"given":"\u00d6zg\u00fcr","family":"G\u00fcnal","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Samsun University, 55080 Samsun, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8856-7356","authenticated-orcid":false,"given":"Ali","family":"Asan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Bursa Y\u00fcksek \u0130htisas Training and Research Hospital, University of Health Sciences, 16310 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5490-465X","authenticated-orcid":false,"given":"Ey\u00fcp","family":"Arslan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Sancaktepe \u015eehit Prof. Dr. \u0130lhan Varank Training and Research Hospital, University of Health Sciences, 34785 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4657-5291","authenticated-orcid":false,"given":"Fatma","family":"Y\u0131lmaz Karada\u011f","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Sancaktepe \u015eehit Prof. Dr. \u0130lhan Varank Training and Research Hospital, University of Health Sciences, 34785 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5347-7740","authenticated-orcid":false,"given":"Or\u00e7un","family":"Barkay","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Y\u0131ld\u0131r\u0131m University, 24100 Erzincan, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-9148","authenticated-orcid":false,"given":"\u0130rem","family":"Akdemir","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ankara University, 06230 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"\u015eim\u015fek","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Prof. Dr. Cemil Ta\u015f\u00e7\u0131o\u011flu City Hospital, University of Health Sciences, 34384 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine","family":"T\u00fcrko\u011flu Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Tokat Gaziosmanpa\u015fa University, 60030 Tokat, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-1077","authenticated-orcid":false,"given":"Zeynep Ravza","family":"E\u011filmez","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erciyes University, 38030 Kayseri, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcda","family":"Tekin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Ac\u0131badem Ata\u015fehir Hospital, 34642 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases (KL\u0130M\u0130K)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization Hepatitis C, World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_2","unstructured":"World Health Organization (2024). Implementing the Global Health Sector Strategies on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2022\u20132030: Report on Progress and Gaps 2024, World Health Organization. [2nd ed.]."},{"key":"ref_3","unstructured":"US Food and Drug Administration (2025, January 21). FDA Approves Vosevi for Hepatitis C, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-vosevi.htm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on the treatment of hepatitis C: Final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_5","first-page":"e131","article-title":"American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America HCV Guidance Panel. Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"77","author":"Bhattacharya","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","unstructured":"Sosyal G\u00fcvenlik Kurumu (2025, March 21). 01.06.2022 Tarihli ve 31853 Say\u0131l\u0131 Resmi Gazete\u2019de Yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finde De\u011fi\u015fiklik Yap\u0131lmas\u0131na Dair Tebli\u011f. Ankara: Sosyal G\u00fcvenlik Kurumu; 2022 Jun 2, Available online: https:\/\/www.sgk.gov.tr\/Duyuru\/Detay\/01062022-tarihli-ve-31853-sayili-Resmi-Gazetede-Yayimlanan-Sosyal-Guvenlik-Kurumu-Saglik-Uygulama-Tebliginde-Degisiklik-Yapilmasina-Dair-Teblig-2022-06-02-04-44-36."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.36519\/kd.2023.4672","article-title":"Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2023 Update\/Kronik Hepatit C Virusu Infeksiyonunun Yonetimi: Turk Klinik Mikrobiyoloji ve Infeksiyon Hastaliklari Dernegi Viral Hepatit Calisma Grubu Uzlasi Raporu-2023 Guncellemesi","volume":"36","author":"Aygen","year":"2023","journal-title":"KLIMIK J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/apt.18020","article-title":"Real-life effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients previously treated with sofosbuvir\/velpatasvir or glecaprevir\/pibrentasvir","volume":"60","author":"Llaneras","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3904\/kjim.2022.252","article-title":"Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: A Phase 3b study","volume":"38","author":"Heo","year":"2023","journal-title":"Korean J. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 Weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1665-2681(19)31836-8","article-title":"AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis","volume":"7","year":"2008","journal-title":"Ann. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/hep.21333","article-title":"FIB-4: A simple, inexpensive and accurate marker of fibrosis in HCV-infected patients","volume":"44","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Devan, P., Tiong, K.L.A., Neo, J.E., Mohan, B.P., Wijarnpreecha, K., Tam, Y.C.S., and Wong, Y.J. (2023). Treatment outcomes of sofosbuvir\/velpatasvir\/voxilaprevir in direct-acting antiviral-experienced hepatitis C virus patients: A systematic review and meta-analysis. Viruses, 15.","DOI":"10.3390\/v15071489"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s40121-022-00666-0","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir as a hepatitis C virus infection salvage therapy in the real world: A systematic review and meta-analysis","volume":"11","author":"Xie","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e3288","DOI":"10.1093\/cid\/ciaa1318","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir\/voxilaprevir for hepatitis C virus (HCV) NS5A-inhibitor experienced patients with difficult to cure characteristics","volume":"73","author":"Papaluca","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e799","DOI":"10.1093\/cid\/ciaa1510","article-title":"Salvage therapy with sofosbuvir\/velpatasvir\/voxilaprevir in DAA-experienced patients: Results from a prospective Canadian registry","volume":"72","author":"Onofrio","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4274\/vhd.galenos.2023.2023-5-2","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir experience in treatment-na\u00efve chronic hepatitis C patients: Preliminary findings of real-world data","volume":"29","author":"Yamazhan","year":"2023","journal-title":"Viral. Hepat. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12072-022-10475-9","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: A real-world multicenter cohort in Taiwan","volume":"17","author":"Liu","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/MEG.0000000000001786","article-title":"Efficacy of sofosbuvir\/velpatasvir\/voxilaprevir in direct-acting antiviral-experienced patients with hepatitis C virus","volume":"33","author":"Da","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","article-title":"Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous DAA failure","volume":"71","author":"Degasperi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s43066-024-00372-1","article-title":"A systematic review of sofosbuvir\/velpatasvir\/voxilaprevir in HCV patients previously treated with direct-acting antivirals","volume":"14","author":"Rustam","year":"2024","journal-title":"Egypt Liver J."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"G\u00fcrb\u00fcz, Y., Kocag\u00fcl-\u00c7elikba\u015f, A., \u00d6ztoprak, N., Aygen, B., Bat\u0131rel, A., Habilo\u011flu, A.D., Aktu\u011f-Demir, N., \u00c7eken, S., Demirt\u00fcrk, N., and Ceylan, M.R. (2024). The Efficacy of Glecaprevir\/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life Data. Infect. Dis. Clin. Microbiol., 6.","DOI":"10.36519\/idcm.2024.344"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/jvh.13399","article-title":"Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination","volume":"27","author":"Drenth","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jiph.2016.06.012","article-title":"Magnitude and causes of loss to follow-up among patients with viral hepatitis at a tertiary care hospital in Saudi Arabia","volume":"10","author":"Balkhy","year":"2017","journal-title":"J. Infect. Public Health"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/7\/931\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:02:06Z","timestamp":1760032926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/7\/931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["v17070931"],"URL":"https:\/\/doi.org\/10.3390\/v17070931","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}